|
1
|
Kroep JR, Peters GJ, van Moorsel CJ, et
al: Gemcitabine-cisplatin: A schedule finding study. Ann Oncol.
10:1503–1510. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
No authors listed. Chemotherapy in
non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomised clinical trials. Non-Small
Cell Lung Cancer Collaborative Group. BMJ. 311:899–909. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
No authors listed. Clinical practice
guidelines for the treatment of unresectable non-small-cell lung
cancer. Adopted on May 16, 1997 by the American Society of Clinical
Oncology. J Clin Oncol. 15:2996–3018. 1997.PubMed/NCBI
|
|
4
|
Berghmans T, Paesmans M, Lalami Y, et al:
Activity of chemotherapy and immunotherapy on malignant
mesothelioma: a systematic review of the literature with
meta-analysis. Lung Cancer. 38:111–121. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Braakhuis BJ, van Dongen GA, Vermorken JB
and Snow GB: Preclinical in vivo activity of
2′,2′-difluorodeoxycytidine (Gemcitabine) against human head and
neck cancer. Cancer Res. 51:211–214. 1991.
|
|
6
|
van Moorsel CJ, Veerman G, Bergman AM, et
al: Combination chemotherapy studies with gemcitabine. Semin Oncol.
24(2 Suppl 7): S7-17–S7-23. 1997.
|
|
7
|
Peters GJ, Ruiz van Haperen VW, Bergman
AM, et al: Preclinical combination therapy with gemcitabine and
mechanisms of resistance. Semin Oncol. 23(5 Suppl 10): 16–24.
1996.PubMed/NCBI
|
|
8
|
Braakhuis BJ, Ruiz van Haperen VW, Welters
MJ and Peters GJ: Schedule-dependent therapeutic efficacy of the
combination of gemcitabine and cisplatin in head and neck cancer
xenografts. Eur J Cancer. 31A:2335–2340. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bergman AM, Ruiz van Haperen VW, Veerman
G, et al: Synergistic interaction between cisplatin and gemcitabine
in vitro. Clin Cancer Res. 2:521–530. 1996.PubMed/NCBI
|
|
10
|
Tsai CM, Chang KT, Chen JY, et al:
Cytotoxic effects of gemcitabine-containing regimens against human
non-small cell lung cancer cell lines which express different
levels of p185neu. Cancer Res. 56:794–801. 1996.
|
|
11
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McKeage MJ: Comparative adverse effect
profiles of platinum drugs. Drug Saf. 13:228–244. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bunn PA Jr: Chemotherapy for advanced
non-small-cell lung cancer: who, what, when, why? J Clin Oncol.
20:23S–33S. 2002.PubMed/NCBI
|
|
14
|
Voigt W, Bulankin A, Müller T, et al:
Schedule-dependent antagonism of gemcitabine and cisplatin in human
anaplastic thyroid cancer cell lines. Clin Cancer Res. 6:2087–2093.
2000.PubMed/NCBI
|
|
15
|
van Moorsel CJ, Pinedo HM, Veerman G, et
al: Scheduling of gemcitabine and cisplatin in Lewis lung tumour
bearing mice. Eur J Cancer. 35:808–814. 1999.PubMed/NCBI
|
|
16
|
Crinò L, Scagliotti G, Marangolo M, et al:
Cisplatin-gemcitabine combination in advanced non-small-cell
lungcancer: a phase II study. J Clin Oncol. 15:297–303. 1997.
|
|
17
|
Zanellato I, Boidi CD, Lingua G, et al: In
vitro anti-mesothelioma activity of cisplatin-gemcitabine
combinations: evidence for sequence-dependent effects. Cancer
Chemother Pharmacol. 67:265–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Voigt W, Bulankin A, Müller T, et al:
Schedule-dependent antagonism of gemcitabine and cisplatin in human
anaplastic thyroid cancer cell lines. Clin Cancer Res. 6:2087–2093.
2000.PubMed/NCBI
|
|
19
|
Jackson RC: Amphibolic drug combinations:
the design of selective antimetabolite protocols based upon the
kinetic properties of multienzyme systems. Cancer Res.
53:3998–4003. 1993.PubMed/NCBI
|
|
20
|
Eastman A: The formation, isolation and
characterization of DNA adducts produced by anticancer platinum
complexes. Pharmacol Ther. 34:155–166. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bunch RT and Eastman A:
7-Hydroxystaurosporine (UCN-01) causes redistribution of
proliferating cell nuclear antigen and abrogates cisplatin-induced
S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ.
8:779–788. 1997.
|
|
22
|
Karagiannis TC and El-Osta A:
Double-strand breaks: signaling pathways and repair mechanisms.
Cell Mol Life Sci. 61:2137–2147. 2004.PubMed/NCBI
|
|
23
|
Bergstralh DT and Sekelsky J: Interstrand
crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet.
24:70–76. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pérol M, Chouaid C, Pérol D, et al:
Randomized, phase III study of gemcitabine or erlotinib maintenance
therapy versus observation, with predefined second-line treatment,
after cisplatin-gemcitabine induction chemotherapy in advanced
non-small-cell lung cancer. J Clin Oncol. 30:3516–3524. 2012.
|
|
25
|
Hida T, Ogawa S, Park JC, et al: Gefitinib
for the treatment of non-small-cell lung cancer. Expert Rev
Anticancer Ther. 9:17–35. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ozaki K, Kishikawa F, Tanaka M, et al:
Histone deacetylase inhibitors enhance the chemosensitivity of
tumor cells with cross-resistance to a wide range of DNA-damaging
drugs. Cancer Sci. 99:376–384. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Donadelli M, Costanzo C, Beghelli S, et
al: Synergistic inhibition of pancreatic adenocarcinoma cell growth
by trichostatin A and gemcitabine. Biochim Biophys Acta.
1773:1095–1106. 2007. View Article : Google Scholar : PubMed/NCBI
|
